TALEN-based gene correction for epidermolysis bullosa

Molecular Therapy

Volumn 21, Issue 6, 2013, Pages 1151-1159

  Osborn, Mark J ^a   Starker, Colby G ^a,b   McElroy, Amber N ^a   Webber, Beau R ^a   Riddle, Megan J ^a   Xia, Lily ^a   Defeo, Anthony P ^a   Gabriel, Richard ^c   Schmidt, Manfred ^c   Von Kalle, Christof ^c   Carlson, Daniel F ^a   Maeder, Morgan L ^d,e   Joung, J Keith ^d,e   Wagner, John E ^a   Voytas, Daniel F ^a,b   Blazar, Bruce R ^a   Tolar, Jakub ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7; GENOMIC DNA; MESSENGER RNA; NUCLEASE; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; COL7A1 GENE; DNA TEMPLATE; DOUBLE STRANDED DNA BREAK; EPIDERMOLYSIS BULLOSA; GENE; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC ENGINEERING; GENETIC SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; STEM CELL GENE THERAPY; TARGETED GENE REPAIR; TERATOMA;

EID: 84878580410     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.56     Document Type: Article

References (49)

1. Hacein-Bey-Abina, S, Garrigue, A, Wang, G P, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
2. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
3. Daya, S and Berns, KI (2008). Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21: 583-593.
4. Thomas, CE, Ehrhardt, A and Kay, MA (2003). Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4: 346-358.
5. Yant, SR, Wu, X, Huang, Y, Garrison, B, Burgess, SM and Kay, MA (2005). Highresolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 25: 2085-2094.
6. Doetschman, T, Gregg, RG, Maeda, N, Hooper, ML, Melton, DW, Thompson, S et al. (1987). Targetted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 330: 576-578.
7. Porteus, MH and Baltimore, D (2003). Chimeric nucleases stimulate gene targeting in human cells. Science 300: 763.
8. Stoddard, BL (2011). Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modifcation. Structure 19: 7-15.
9. Pâques, F and Duchateau, P (2007). Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. Curr Gene Ther 7: 49-66.
10. Ramirez, CL, Foley, JE, Wright, DA, Müller-Lerch, F, Rahman, SH, Cornu, TI et al. (2008). Unexpected failure rates for modular assembly of engineered zinc fngers. Nat Methods 5: 374-375.
11. Maeder, ML, Thibodeau-Beganny, S, Osiak, A, Wright, DA, Anthony, RM, Eichtinger, M et al. (2008). Rapid "open-source" engineering of customized zinc-fnger nucleases for highly effcient gene modifcation. Mol Cell 31: 294-301.
12. Maeder, ML, Thibodeau-Beganny, S, Sander, JD, Voytas, DF and Joung, JK (2009). Oligomerized pool engineering (OPEN): an 'open-source' protocol for making customized zinc-fnger arrays. Nat Protoc 4: 1471-1501.
13. Pruett-Miller, SM, Connelly, JP, Maeder, ML, Joung, JK and Porteus, MH (2008). Comparison of zinc fnger nucleases for use in gene targeting in mammalian cells. Mol Ther 16: 707-717.
14. Mali, P, Yang, L, Esvelt, KM, Aach, J, Guell, M, DiCarlo, JE et al. (2013). RNA-guided human genome engineering via Cas9. Science 339: 823-826.
15. Cong, L, Ran, FA, Cox, D, Lin, S, Barretto, R, Habib, N et al. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823.
16. Hwang, WY, Fu, Y, Reyon, D, Maeder, ML, Tsai, SQ, Sander, JD et al. (2013). Effcient genome editing in zebrafsh using a CRISPR-Cas system. Nat Biotechnol 31: 227-229.
17. Christian, M, Cermak, T, Doyle, EL, Schmidt, C, Zhang, F, Hummel, A et al. (2010). Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186: 757-761.
18. Cermak, T, Doyle, EL, Christian, M, Wang, L, Zhang, Y, Schmidt, C et al. (2011). Effcient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 39: e82.
19. Fine, JD and Mellerio, JE (2009). Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol 61: 387-402; quiz 403.
20. Wagner, JE, Ishida-Yamamoto, A, McGrath, JA, Hordinsky, M, Keene, DR, Woodley, DT et al. (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 363: 629-639.
21. Wong, T, Gammon, L, Liu, L, Mellerio, JE, Dopping-Hepenstal, PJ, Pacy, J et al. (2008). Potential of fbroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128: 2179-2189.
22. Tolar, J, Ishida-Yamamoto, A, Riddle, M, McElmurry, RT, Osborn, M, Xia, L et al. (2009). Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 113: 1167-1174.
23. Doyle, EL, Booher, NJ, Standage, DS, Voytas, DF, Brendel, V P, Vandyk, JK et al. (2012). TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res 40(Web Server issue): W117-W122.
24. Reyon, D, Tsai, SQ, Khayter, C, Foden, JA, Sander, JD and Joung, JK (2012). FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30: 460-465.
25. Bogdanove, AJ and Voytas, DF (2011). TAL effectors: customizable proteins for DNA targeting. Science 333: 1843-1846.
26. Moscou, MJ and Bogdanove, AJ (2009). A simple cipher governs DNA recognition by TAL effectors. Science 326: 1501.
27. Boch, J, Scholze, H, Schornack, S, Landgraf, A, Hahn, S, Kay, S et al. (2009). Breaking the code of DNA binding specifcity of TAL-type III effectors. Science 326: 1509-1512.
28. Carlson, DF, Tan, W, Lillico, SG, Stverakova, D, Proudfoot, C, Christian, M et al. (2012). Effcient TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci USA 109: 17382-17387.
29. Guschin, DY, Waite, AJ, Katibah, GE, Miller, JC, Holmes, MC and Rebar, EJ (2010). A rapid and general assay for monitoring endogenous gene modifcation. Methods Mol Biol 649: 247-256.
30. Gabriel, R, Lombardo, A, Arens, A, Miller, JC, Genovese, P, Kaeppel, C et al. (2011). An unbiased genome-wide analysis of zinc-fnger nuclease specifcity. Nat Biotechnol 29: 816-823.
31. Paruzynski, A, Arens, A, Gabriel, R, Bartholomae, CC, Scholz, S, Wang, W et al. (2010). Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc 5: 1379-1395.
32. Miller, JC, Tan, S, Qiao, G, Barlow, KA, Wang, J, Xia, DF et al. (2011). A TALE nuclease architecture for effcient genome editing. Nat Biotechnol 29: 143-148.
33. Pattanayak, V, Ramirez, CL, Joung, JK and Liu, DR (2011). Revealing off-target cleavage specifcities of zinc-fnger nucleases by in vitro selection. Nat Methods 8: 765-770.
34. Cheng, L, Blazar, B, High, K and Porteus, M (2011). Zinc fngers hit off target. Nat Med 17: 1192-1193.
35. Mátrai, J, Cantore, A, Bartholomae, CC, Annoni, A, Wang, W, Acosta-Sanchez, A et al. (2011). Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specifc tolerance in mice with low genotoxic risk. Hepatology 53: 1696-1707.
36. Urnov, FD, Miller, JC, Lee, YL, Beausejour, CM, Rock, JM, Augustus, S et al. (2005). Highly effcient endogenous human gene correction using designed zinc-fnger nucleases. Nature 435: 646-651.
37. Elliott, B and Jasin, M (2001). Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells. Mol Cell Biol 21: 2671-2682.
38. Elliott, B, Richardson, C, Winderbaum, J, Nickoloff, JA and Jasin, M (1998). Gene conversion tracts from double-strand break repair in mammalian cells. Mol Cell Biol 18: 93-101.
39. Goto, M, Sawamura, D, Ito, K, Abe, M, Nishie, W, Sakai, K et al. (2006). Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa. J Invest Dermatol 126: 766-772.
40. Yan, WF and Murrell, DF (2010). Fibroblast-based cell therapy strategy for recessive dystrophic epidermolysis bullosa. Dermatol Clin 28: 367-70, xii.
41. Osborn, MJ, DeFeo, A P, Blazar, BR and Tolar, J (2011). Synthetic zinc fnger nuclease design and rapid assembly. Hum Gene Ther 22: 1155-1165.
42. Gibson, DG, Young, L, Chuang, RY, Venter, JC, Hutchison, CA 3rd and Smith, HO (2009). Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6: 343-345.
43. Doyon, Y, Choi, VM, Xia, DF, Vo, TD, Gregory, PD and Holmes, MC (2010). Transient cold shock enhances zinc-fnger nuclease-mediated gene disruption. Nat Methods 7: 459-460.
44. Tolar, J, Xia, L, Lees, CJ, Riddle, M, McElroy, A, Keene, DR et al. (2013). Keratinocytes from induced pluripotent stem cells in junctional epidermolysis bullosa. J Invest Dermatol 133: 562-565.
45. Tolar, J, Xia, L, Riddle, MJ, Lees, CJ, Eide, CR, McElmurry, RT et al. (2011). Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 131: 848-856.
46. Vargas, J Jr, Gusella, GL, Najfeld, V, Klotman, ME and Cara, A (2004). Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 15: 361-372.
47. Schmidt, M, Schwarzwaelder, K, Bartholomae, C, Zaoui, K, Ball, C, Pilz, I et al. (2007). High-resolution insertion-site analysis by linear amplifcation-mediated PCR (LAM-PCR). Nat Methods 4: 1051-1057.
48. Dsouza, M, Larsen, N and Overbeek, R (1997). Searching for patterns in genomic data. Trends Genet 13: 497-498.
49. Arens, A, Appelt, JU, Bartholomae, CC, Gabriel, R, Paruzynski, A, Gustafson, D et al. (2012). Bioinformatic clonality analysis of next-generation sequencing-derived viral vector integration sites. Hum Gene Ther Methods 23: 111-118.